AGM/EGMJun 18, 2026, 04:07 PM
Processa Pharmaceuticals Schedules 2026 Annual Meeting; Proposes Director Elections, Incentive Plan Update
AI Summary
Processa Pharmaceuticals, Inc. has filed its DEF 14A Proxy Statement detailing the upcoming 2026 Annual Meeting of Stockholders scheduled for July 30, 2026. Key proposals include the election of six directors, an amendment to the 2019 Omnibus Incentive Plan to increase available shares by 200,000, ratification of Cherry Bekaert, LLP as the independent auditor, and an advisory vote on executive compensation. The company is utilizing the internet for proxy material delivery to reduce costs.
Key Highlights
- Processa Pharmaceuticals to hold 2026 Annual Meeting of Stockholders on July 30, 2026.
- Proposals include election of six directors, amendment to 2019 Omnibus Incentive Plan, ratification of auditor, and advisory vote on executive compensation.
- The company seeks to increase shares available under the Incentive Plan by 200,000 shares.
- Cherry Bekaert, LLP proposed as independent registered public accounting firm for fiscal year ending December 31, 2026.
Price Impact
More from PCSA